17.94 0.00 (0.00%)
After hours: 5:55PM EDT
|Bid||17.93 x 800|
|Ask||20.00 x 1400|
|Day's Range||17.86 - 18.50|
|52 Week Range||9.38 - 20.90|
|Beta (3Y Monthly)||-0.94|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Athenex (ATNX) shares rise on encouraging preliminary data from an early-stage study on KX2-391, currently under development for treating patients with psoriasis.
Dr. Reddy's (RDY) reports positive top-line results from the phase IIb study on PPC-06 (formerly referred to as XP23829) in patients with moderate to severe plaque psoriasis.
On a per-share basis, the Buffalo, New York-based company said it had a loss of 53 cents. The biopharmaceutical company posted revenue of $25.3 million in the period. Athenex shares have risen slightly ...
Two major healthcare investment entities are investing $100 million in Athenex, a potential sign of things to come.
Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips on the charts, usually don't make them change their opinion towards a company. This time it may be different. During the fourth quarter of 2018 we observed increased volatility and small-cap stocks underperformed the market. Hedge […]
Details the CEO buys this past week for the following companies: Continental Resources, New Fortress Energy, Athenex, FS KKR Capital and Federal Agricultural Mortgage
Athenex Inc is a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer. The price of the stock has decreased by 0.16% since.
Athenex Inc is a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer. Warning! GuruFocus has detected 3 Warning Signs with ATNX.
Results from the Phase 3 study of Athenex's leading drug candidate will be published in the middle of this year, potentially signaling to the world the arrival of its technology.
On a per-share basis, the Buffalo, New York-based company said it had a loss of 41 cents. The biopharmaceutical company posted revenue of $21.3 million in the period. For the year, the company reported ...
The number was inflated by the surging ACV Auctions, an online platform for wholesale car auctions, which was founded in 2014 and closed Series C and D venture capital rounds last year that totaled $124 million. It is undoubtedly the biggest story in Buffalo tech, but it’s not the sole reason 2018 was a record-breaking year. The portfolio of startups that received funding in Buffalo last year reflect the city’s economic diversity, along with the development strategies of recent years.
The fast-growing drug development company expects to data this year on its two leading chemotherapy drugs. The pharmaceutical world is watching.
A look at the shareholders of Athenex, Inc. (NASDAQ:ATNX) can tell us which group is most powerful. Institutions often own shares in more established companies, while it's not unusual to Read More...
CEO and Chairman of the Board of Athenex Inc (NASDAQ:ATNX) Johnson Yiu Nam Lau bought 10,000 shares of ATNX on 11/19/2018 at an average price of $11.75 a share.